January 31, 2015     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the U.S. Food and Drug Administration (FDA) approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension. more info >>
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
On December 5, Otsuka Pharmaceutical is launching a new form of L-Cartin, L-Cartin Free Form (FF) tablets (generic name levocarnatine) in two doses, 100mg and 250mg. more info >>
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Nitto Denko Corporation (Nitto) announced the initiation of a phase-1b clinical study in the US started in September 2014, to administer a new anti-fibrosis drug in patients for the assessment of safety and efficacy. more info >>
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
ACN Newswire
 Press Release News

Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint (Jan 30, 2015)
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Phase II part of a Phase I/II clinical trial (Study 205) of its in-house developed anticancer agent lenvatinib mesylate (lenvatinib) in unresectable advanced or metastatic renal cell carcinoma has met its primary endpoint. more info >>
Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines (Jan 26, 2015)
Eisai Co., Ltd. and Ajinomoto Pharmaceuticals Co., Ltd. announced today that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines. more info >>
Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year (Jan 23, 2015)
Eisai Co., Ltd. announced today that it has been listed in the 2015 Global 100 Most Sustainable Corporations in the World (Global 100) Index, a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >>
Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Conducted in Asia Including Japan and China Meets Primary Endpoint (Jan 5, 2015)
Eisai Co., Ltd. announced today that a Phase III clinical trial (Study 335) of its in-house-discovered antiepileptic drug (AED) perampanel in patients with refractory partial-onset seizures conducted in Asia (including Japan and China) has met its primary endpoint. more info >>
Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment (Dec 17, 2014)
Eisai Co., Ltd. announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment. more info >>
 Global Press Release

Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint (Jan 30, 2015)

Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines (Jan 26, 2015)

Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year (Jan 23, 2015)

Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Conducted in Asia Including Japan and China Meets Primary Endpoint (Jan 5, 2015)

A*STAR Scientists Discover Gene Critical for Proper Brain Development (Dec 19, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)